-
Whether they want to lose a few pounds that were added over the holidays or develop a more comprehensive weight-loss goal, many of your patients will resolve to lose weight in the new year.
-
La Puma J. Coenzyme Q10 and Parkinson's disease. Altern Med Alert 2003;6(1):12.
-
O'Mathuna DP. Anabolic-androgenic steroids for athletes: Adverse effects. Altern Med Alert 2003;6(1):8-11.
-
Ramalanjaona G. Ginkgo biloba for memory enhancement: An update. Altern Med Alert 2003;6(1):1-5.
-
-
Nardino RJ. Chitosan for weight loss and cholesterol lowering. Altern Med Alert 2003;6(1):5-8.
-
Effects of Losartan on Cardiovascular Morbidity and Mortality in
Patients with Isolated Systolic Hypertension and LVH; Increase in
Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1
Diabetes; HRT, Lipid, and Glucose Metabolism in Diabetic and
Nondiabetic Postmenopausal Women; Effects of Long-Term Treatment With
ACE Inhibitors in the Presence or Absence of Aspirin; Long-Term Risks
Associated with Atrial Fibrillation: 20-Year Follow-up of the
Renfrew/Paisley Study; Olfactory Impairment in Older Adults
-
FDA Approves Claritin For OTC Use For Seasonal Rhinitis; Simpler Atrial Fibrillation Management; Oral Anticoagulation Vs Aspirin in AF; Immunization Does Not Cause Autism; Statins May Lower CRP Levels; Simvastatin Reduced CRP Plasma Levels; FDA Actions
-
Aripiprazole (Abilify), a new drug for schizophrenia, received FDA approval November 15; on November 14, Neurocrine Biosciences Inc. announced positive results from its first phase III clinical trial with indiplon-IR achieving primary and secondary end points of sleep initiation.
-
The results of 3 recent investigations suggest that immunotherapy still has the potential to become a treatment for AD but that the road to its successful development is likely to be a long one.